Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors.

Kim CH, Cheon KA, Koo MS, Ryu YH, Lee JD, Chang JW, Lee HS.

Neuropsychobiology. 2007;55(3-4):156-62. Epub 2007 Jul 26.

PMID:
17657168
2.

Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder.

Kim CH, Koo MS, Cheon KA, Ryu YH, Lee JD, Lee HS.

Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):1637-43. Epub 2003 Sep 25.

PMID:
14513291
3.

Dopamine transporter density of the basal ganglia assessed with [123I]IPT SPECT in drug-naive children with Tourette's disorder.

Cheon KA, Ryu YH, Namkoong K, Kim CH, Kim JJ, Lee JD.

Psychiatry Res. 2004 Jan 15;130(1):85-95.

PMID:
14972371
4.

Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder.

Cheon KA, Ryu YH, Kim YK, Namkoong K, Kim CH, Lee JD.

Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):306-11. Epub 2002 Nov 29.

PMID:
12552351
5.

Changes in thalamus-hypothalamus serotonin transporter availability during clomipramine administration in patients with obsessive-compulsive disorder.

Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Wenzel T, Zettinig G, Hornik K, Pirker W, Thau K.

Neuropsychopharmacology. 2008 Dec;33(13):3126-34. doi: 10.1038/npp.2008.35. Epub 2008 Mar 19.

6.

Serotonin and dopamine transporter imaging in patients with obsessive-compulsive disorder.

Hesse S, Müller U, Lincke T, Barthel H, Villmann T, Angermeyer MC, Sabri O, Stengler-Wenzke K.

Psychiatry Res. 2005 Oct 30;140(1):63-72. Epub 2005 Oct 6.

PMID:
16213689
7.

Diencephalic serotonin transporter availability predicts both transporter occupancy and treatment response to sertraline in obsessive-compulsive checkers.

Zitterl W, Stompe T, Aigner M, Zitterl-Eglseer K, Ritter K, Zettinig G, Hornik K, Asenbaum S, Pirker W, Thau K.

Biol Psychiatry. 2009 Dec 15;66(12):1115-22. doi: 10.1016/j.biopsych.2009.07.009. Epub 2009 Aug 29.

PMID:
19717141
8.

Serotonin transporter imaging with [123I]beta-CIT SPECT before and after one year of citalopram treatment of obsessive-compulsive disorder.

Stengler-Wenzke K, Müller U, Barthel H, Angermeyer MC, Sabri O, Hesse S.

Neuropsychobiology. 2006;53(1):40-5. Epub 2006 Jan 4.

PMID:
16397403
9.

Dosimetry of an iodine-123-labeled tropane to image dopamine transporters.

Mozley PD, Stubbs JB, Kim HJ, McElgin W, Kung MP, Meegalla S, Kung HF.

J Nucl Med. 1996 Jan;37(1):151-9.

10.

Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.

Humble MB, Uvnäs-Moberg K, Engström I, Bejerot S.

BMC Psychiatry. 2013 Dec 23;13:344. doi: 10.1186/1471-244X-13-344.

11.
12.

[Pharmacological treatments for obsessive-compulsive disorder and the serotonin-dopamine hypothesis].

Okamoto Y.

Seishin Shinkeigaku Zasshi. 2011;113(1):36-44. Japanese.

PMID:
21404630
13.

[123I]-beta-CIT SPECT imaging shows reduced thalamus-hypothalamus serotonin transporter availability in 24 drug-free obsessive-compulsive checkers.

Zitterl W, Aigner M, Stompe T, Zitterl-Eglseer K, Gutierrez-Lobos K, Schmidl-Mohl B, Wenzel T, Demal U, Zettinig G, Hornik K, Thau K.

Neuropsychopharmacology. 2007 Aug;32(8):1661-8. Epub 2006 Dec 27.

14.

Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder.

Denys D, van der Wee N, Janssen J, De Geus F, Westenberg HG.

Biol Psychiatry. 2004 May 15;55(10):1041-5.

PMID:
15121489
15.

Right basal ganglion hypoperfusion in obsessive compulsive disorder patients demonstrated by Tc-99m-HMPAO brain perfusion spect: a controlled study.

Topçuoglu V, Cömert B, Karabekiroglu A, Dede F, Erdil TY, Turoglu HT.

Int J Neurosci. 2005 Dec;115(12):1643-55.

PMID:
16287631
16.

SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD).

Pogarell O, Poepperl G, Mulert C, Hamann C, Sadowsky N, Riedel M, Moeller HJ, Hegerl U, Tatsch K.

Eur Neuropsychopharmacol. 2005 Oct;15(5):521-4.

PMID:
16139170
17.

Reduced serotonin transporter-availability in obsessive-compulsive disorder (OCD).

Stengler-Wenzke K, Müller U, Angermeyer MC, Sabri O, Hesse S.

Eur Arch Psychiatry Clin Neurosci. 2004 Aug;254(4):252-5.

PMID:
15309396
18.

Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I.

Ziebell M, Holm-Hansen S, Thomsen G, Wagner A, Jensen P, Pinborg LH, Knudsen GM.

J Nucl Med. 2010 Dec;51(12):1885-91. doi: 10.2967/jnumed.110.078337. Epub 2010 Nov 15. Erratum in: J Nucl Med. 2011 Jan;52(1):106.

19.

Serotonin transporter binding in Tourette Syndrome.

Müller-Vahl KR, Meyer GJ, Knapp WH, Emrich HM, Gielow P, Brücke T, Berding G.

Neurosci Lett. 2005 Sep 9;385(2):120-5.

PMID:
15936877
20.

[Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes].

Zhang L, Liu X, Li T, Yang Y, Hu X, Collier D.

Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2004 Oct;21(5):479-81. Chinese.

PMID:
15476175

Supplemental Content

Support Center